DUSA PHARMACEUTICALS INC. - 500 Beiträge pro Seite

[heimleiter]

Wer kann mir etwas über Dusa Pharmaceuticals sagen?
Habe den Wert als Outperformer mit Kursziel 100 ans Herz gelegt bekommen.

[madmurdock]

Dusa Pharmaceutical hat ein lichtaktiviertes Krebspräparat entwickelt, daß bei der Heilung von Hautkrebs rein die bösartigen Krebszellen mit speziellem Laser vernichtet und nicht auch gleichzeitig gesundes Gewebe.
Wobei in letzter Zeit hohe Blockverkäufe stattfanden, was auf schlechte Nachrichten hinweisen könnte. Hier würde ich noch abwarten. Der Informationsdienst CUTTING EDGE empfiehl momentan auch zu verkaufen.

MfG

madmurdock

[defizit1]

Gestern von der Telebörse empfohlen worden mit nur einem Risikostern bei 4 möglichen und 3 Chancesternen bei 4 möglichen. Überhaupt hörte sich der Bericht vielversprechend an - ich habe mir ein paar ins Depot gelegt - seht Euch den wert mal an !!
mfg
defizit1

[defizit1]

Und schon gehts 10 % nach oben !!!!

Monday December 11, 8:52 am Eastern Time
Press Release
DUSA Pharmaceuticals, Inc. - Positive Independent Results In A Randomized Study Using Levulan PDT To Treat Dysplastic Barrett`s Esophagus
WILMINGTON, Mass.--(BUSINESS WIRE)--Dec. 11, 2000--DUSA Pharmaceuticals, Inc. (NASDAQ: DUSA - news) is pleased to report that independent investigators at the University of Sheffield, UK, have published the results of the first randomized clinical study using LEVULAN®(aminolevulinic acid HCl) Photodynamic Therapy (PDT) to treat dysplastic (precancerous) Barrett`s esophagus in 36 subjects.

Barrett`s esophagus (BE) is an acquired condition affecting up to 700,000 patients in the United States, in which the normal esophageal lining is replaced by an abnormal lining that can then become dysplastic. As dysplasia progresses from low-grade to high-grade, the risk of esophageal cancer greatly increases, such that patients with confirmed high-grade dysplasia often undergo major surgery to remove the affected portion of the esophagus. Current medical treatment of BE includes lifelong anti-reflux therapy with drugs called proton pump inhibitors. The role of anti-reflux surgery is also being evaluated. There is currently no approved therapy proven to halt or reverse BE, or to slow its progression to esophageal cancer.

In this double blind, placebo controlled study, patients with low-grade dysplastic BE, on chronic medical (drug) therapy, were randomized to receive oral LEVULAN® (30 mg/kg) or placebo. Four hours later, up to 6 cm of BE in each patient was treated with green laser light (514 nm) via an endoscope, to a total light dose of 60 J/cm2 . Follow up endoscopy and biopsy procedures were performed at 1, 6, 12, and 24 months following the PDT treatment. A response was seen in 16/18 (89%) patients in the LEVULAN® group, with a median decrease in area of BE averaging 30% (range = 0-60%). In the placebo group, a median area decrease of 0% was seen (range 0-10%). In the LEVULAN® PDT group, all the areas that responded remained normal over the entire 24-month follow-up period, and no dysplasia was observed in treated areas where BE was still present. In the placebo group, persistent low-grade dysplasia was found in 12/18 (67%) patients followed for 24 months.

The investigators indicated that the only consistent side effect of LEVULAN® PDT seen in all treated patients was some degree of chest pain during light treatment, but analgesia was required in only 3/18 (17%). One patient developed a mild rash after exposure to sunlight on the day after treatment. None of the patients developed strictures or complained of difficulty swallowing during the course of the study. No laboratory abnormalities were reported.

This is the first prospective, randomized double-blind, placebo-controlled trial of LEVULAN® PDT for Barrett`s esophagus reported in the literature. This study corroborates and extends results published from other smaller, uncontrolled clinical studies. DUSA continues to support this indication, and a new LEVULAN® dose-ranging protocol is about to be initiated by the same investigators, using a 635 nm diode laser provided by DUSA Pharmaceuticals, Inc.

Stuart Marcus, MD, DUSA`s VP, Scientific Affairs, and CSO, stated ``We are excited by the results of this well-designed independent study from the University of Sheffield, demonstrating a significant and prolonged effect of LEVULAN®PDT on dysplastic BE, for which there is no proven effective therapy. DUSA is sufficiently encouraged by the results of this trial to continue to support the investigators and to work with them on the effective delivery of LEVULAN® PDT to optimize dysplastic BE ablation. We are also planning a DUSA study on this indication in the near future.``

The paper, published in the journal Gut [Volume 47, pages 612-617 (2000)], is titled ``Photodynamic therapy for dysplastic Barrett`s esophagus: a prospective, double blind, randomized, placebo controlled trial``, by R Ackroyd, N J Brown, MF Davis, T J Stephenson, S L Marcus, C J Stoddard, A G Johnson, and M W R Reed.

DUSA Pharmaceuticals, Inc. is a biopharmaceutical company engaged primarily in the development of LEVULAN® Photodynamic Therapy (PDT) and Photodetection (PD) for multiple medical indications. PDT and PD utilize light-activated compounds such as LEVULAN® to induce a therapeutic or detection effect. DUSA is a world leader in topically or locally applied PDT and PD. The Company is incorporated in New Jersey, with offices in Wilmington, MA, Valhalla, NY, and Toronto, Ontario.

Except for historical information, this news release contains certain forward-looking statements that involve known and unknown risk and uncertainties, which may cause actual results to differ materially from any future results, performance or achievements expressed or implied by the statements made. These forward-looking statements relate to DUSA`s support for the development of LEVULAN® for Barrett`s esophagus, the intention to work towards a DUSA study for this indication, and the timing and parameters of the study. Such risks and uncertainties include, but are not limited to, the regulatory requirements to begin new trials, the results of clinical trials, development of an appropriate light device and other risks identified in DUSA`s SEC filings from time to time.